Share
In the most recent trading session, shares of Magenta Therapeutics Inc. (NASDAQ: MGTA) rose by 51.66%.
In the most recent trading session, shares of Magenta Therapeutics Inc. (NASDAQ: MGTA) rose by 51.66%.
Why: The clinical-stage biotechnology firm Magenta Therapeutics (Nasdaq: MGTA), which aims to enhance stem cell transplantation, has reported that it has finished an assessment of its operations, including the state of its programs, resources, and capabilities.
Magenta will look into possible strategic options during the review process, including but not restricted to an acquisition, merger, business combination, or other transaction. And there can be no guarantee that Magenta will pursue a deal as a consequence of this review process or that any transaction, if pursued, would be completed on favorable terms.
Magenta Therapeutics does not intend to speak more until the Board of Directors has adopted a clear course of action, the review process is complete, or it is considered that additional disclosure is necessary. The company has not established a deadline for the conclusion of this review process.
.svg)
.a80ca33.svg)
%20(1).svg)
.svg){kind=icon}
%20(1).svg){kind=icon}
.svg)
